Hostname: page-component-65b85459fc-cljkw Total loading time: 0 Render date: 2025-10-17T06:10:25.633Z Has data issue: false hasContentIssue false
  • English
  • Français

Clozapine: the Holywell experience with the first 24 patients

Published online by Cambridge University Press:  13 June 2014

David J King  and
Philip J Mills
David J King*
Affiliation:
Department of Therapeutics and Pharmacology, The Queen's University of Belfast, Whitla Medical Building, 97 Lisburn Road, Belfast BT9 7BL and Holywell Hospital, Antrim BT41 2RJ, Northern Ireland
Philip J Mills
Affiliation:
Department of Therapeutics and Pharmacology, The Queen's University of Belfast, Whitla Medical Building, 97 Lisburn Road, Belfast BT9 7BL and Holywell Hospital, Antrim BT41 2RJ, Northern Ireland
*
(Department of Therapeutics and Pharmacology)
Get access Rights & Permissions [Opens in a new window]

Abstract

Clozapine was substituted for standard antipsychotic drugs in the treatment of 24 chronic schizophrenic inpatients and the response assessed after a mean of ten months. The majority (71%) improved (33.3% markedly), on their previous level of functioning. The response was better in those under 40 years of age, but neither duration of illness nor previous neuroleptic dose appeared to predict response to clozapine. The drug was ultimately discontinued in five (21%) patients – in three because of non-response and intolerance of sedation and in two because of neutropenia.

Keywords

ClozapineChronic schizophreniaResponse prediction

Information

Type
Clinical & Brief Reports
Information
Irish Journal of Psychological Medicine , Volume 10 , Issue 1 , February 1993 , pp. 30 - 34
Copyright
Copyright © Cambridge University Press 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1.Adams, C. Working with clozapine. Psychiatr Bull 1991; 15: 336–8.CrossRefGoogle Scholar
2.Cutting, J, Reveley, A. Expert opinion: clozapine. Psychiatr Bull 1991; 15: 617.CrossRefGoogle Scholar
3.Launer, MA. Personal experience with clozapine. Psychiatr Bull 1991; 15: 223–4.CrossRefGoogle Scholar
4.Launer, MA. Use of clozapine. Psychiatr Bull 1992; 16: 45–6.CrossRefGoogle Scholar
5.American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington DC: American Psychiatric Association, 1980.Google Scholar
6.Davis, JM. Comparative doses and costs of antipsychotic medication. Arch Gen Psychiatry 1976; 33: 858–61.CrossRefGoogle ScholarPubMed
7.Suy, E, Woestenborghs, R, Heykants, J. Bioavailability and clinical effect of two different concentrations of haloperidol decanoate. Curr Ther Res 1982; 31: 982–91.Google Scholar
8.Foster, P. Neuroleptic equivalence. Pharmaceut J 1989; 09 30: 431–2.Google Scholar
9.Haller, E, Binder, RL. Clozapine and seizures. Am J Psychiatry 1990; 147: 1069–71.Google ScholarPubMed
10.Tiihonen, J, Nousiainen, U, Hakola, P, Leinonen, E, Tuunainen, A, Mervaala, E, Paanila, J. EEG abnormalities associated with clozapine treatment. Am J Psychiatry 1991; 148: 1406.Google ScholarPubMed
11.Kane, J, Honigfeld, G, Singer, J, Meitzer, H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96.CrossRefGoogle ScholarPubMed
12.Clozapine Study Group. The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK. Br J Psych 1993 (submitted for publication).Google Scholar
13.Lindström, LH. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 1988; 77: 524–9.CrossRefGoogle ScholarPubMed
14.Wilson, WH. Clinical review of clozapine treatment in a state hospital. Hosp Comm Psychiatry 1992; 43: 700–3.Google ScholarPubMed
15.Revicki, DA, Luce, BR, Weschler, JM, Brown, RE, Adler, MA. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Comm Psychiatry 1990; 41: 850–4.Google ScholarPubMed